Shares of Stemline Therapeutics Inc. (NASDAQ:STML) were up 3.3% on Monday . The stock traded as high as $7.32 and last traded at $7.30, with a volume of 81,001 shares traded. The stock had previously closed at $7.07.

Several analysts have weighed in on STML shares. Jefferies Group reissued a “buy” rating and set a $23.00 target price on shares of Stemline Therapeutics in a research report on Monday, June 6th. Roth Capital reissued a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a research report on Tuesday, May 10th. Zacks Investment Research raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research report on Wednesday, July 6th. Finally, Wedbush reissued an “outperform” rating and set a $16.00 target price on shares of Stemline Therapeutics in a research report on Tuesday, June 7th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Stemline Therapeutics has an average rating of “Buy” and a consensus price target of $19.56.

The company’s 50 day moving average is $7.39 and its 200 day moving average is $5.72. The firm’s market capitalization is $127.31 million.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.08. The business had revenue of $205.65 million for the quarter, compared to analyst estimates of $121.43 million. On average, equities analysts predict that Stemline Therapeutics Inc. will post ($2.23) earnings per share for the current year.

An institutional investor recently raised its position in Stemline Therapeutics stock. Royce & Associates LLC boosted its stake in shares of Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned 0.91% of Stemline Therapeutics worth $1,004,000 as of its most recent SEC filing.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.